IMGT engineered variant nomenclature: IGHG variants

Citing this table: Lefranc, M.-P. and Lefranc, G., The Immunoglobulin FactsBook, Academic Press, London, UK (458 pages), 2001, ISBN:012441351X

1. Structural and biological properties of human immunoglobulins

2. Human immunoglobulin (IG) chain characteristics

3. IG interchain disulfide bridges per monomer

4. Lysines and cysteines of the Homo sapiens IGHG1, IGKC and IGLC1 and positions in the C-DOMAIN

5. Amino acid positions involved in ADCC, ADCP, CDC, half-life and half-IG exchange

7. Homo sapiens IGHG1 amino acids involved in the interactions with the C1q, FcγR and FCGRT

Species	IMGT gene name	IMGT engineered variant nomenclature	IGHG gene variant description					Property modifications
Species	IMGT gene name	IMGT engineered variant nomenclature	IMGT IGHG gene variant number	hinge (h) or CH2	AA and IMGT position in h or CH2 of IGHG gene variant	CH3	AA and IMGT position in CH3 of IGHG gene variant	ADCC enhancement or reduction, ADCP enhancement, B cell inhibition	CDC enhancement or reduction	Half-IG exchange reduction, Half-life increase, Knobs-into-holes
Homo sapiens	IGHG1	Homsap IGHG1v1 CH2 P1.4	v1	CH2	P1.4			ADCC reduction
		Homsap IGHG1v2 CH2 V1.3	v2	CH2	V1.3			ADCC reduction
		Homsap IGHG1v3 CH2 A1.2	v3	CH2	A1.2			ADCC reduction
		Homsap IGHG1v4 CH2 A114	v4	CH2	A114			ADCC reduction	CDC reduction
		Homsap IGHG1v5 CH2 W109	v5	CH2	W109			ADCC reduction	CDC enhancement
		Homsap IGHG1v6 CH2 A85.4, A118, A119	v6	CH2	A85.4, A118, A119			ADCC enhancement
		Homsap IGHG1v7 CH2 D3, E117	v7	CH2	D3, E117			ADCC enhancement
		Homsap IGHG1v8 CH2 D3, L115, E117	v8	CH2	D3, L115, E117			ADCC enhancement	CDC reduction
		Homsap IGHG1v9 CH2 L7, P83, L85.2, I88; CH3 L83	v9	CH2	L7, P83, L85.2, I88	CH3	L83	ADCC enhancement
		Homsap IGHG1v10 CH2 Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4	v10	CH2	Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4			ADCC enhancement
		Homsap IGHG1v11 CH2 E34, D109, M115, E119	v11	CH2	E34, D109, M115, E119			ADCC enhancement
		Homsap IGHG1v12 CH2 A1.1, D3, L115, E117	v12	CH2	A1.1, D3, L115, E117			ADCC enhancement
		Homsap IGHG1v13 CH2 A1.1, D3, E117	v13	CH2	A1.1, D3, E117			ADCP enhancement
		Homsap IGHG1v14 CH2 A1.3, A1.2	v14	CH2	A1.3, A1.2			ADCC reduction	CDC reduction
		Homsap IGHG1v14-1 CH2 A1.3, A1.2, A1	v14-1	CH2	A1.3, A1.2, A1			ADCC reduction	CDC reduction
		Homsap IGHG1v14-4 CH2 A1.3, A1.2, A114	v14-4	CH2	A1.3, A1.2, A114			ADCC reduction	CDC reduction
		Homsap IGHG1v14-48 CH2 A1.3, A1.2, R113	v14-48	CH2	A1.3, A1.2, R113			ADCC reduction	CDC reduction
		Homsap IGHG1v14-49 CH2 A1.3, A1.2, G114	v14-49	CH2	A1.3, A1.2, G114			ADCC reduction	CDC reduction
		Homsap IGHG1v14-67 CH2 A1.3, A1.2, S27	v14-67	CH2	A1.3, A1.2, S27			ADCC reduction	CDC reduction
		Homsap IGHG1v15 CH2 S118	v15	CH2	S118				CDC enhancement
		Homsap IGHG1v16 CH2 W109, S118	v16	CH2	W109, S118				CDC enhancement
		Homsap IGHG1v17 CH2 E29, F30, T107	v17	CH2	E29, F30, T107				CDC enhancement
		Homsap IGHG1v18 CH3 R1, G109, Y120	v18			CH3	R1, G109, Y120		CDC enhancement
		Homsap IGHG1v19 CH2 A34	v19	CH2	A34				CDC reduction
		Homsap IGHG1v20 CH2 A105	v20	CH2	A105				CDC reduction
		Homsap IGHG1v21 CH2 Y15.1, T16, E18	v21	CH2	Y15.1, T16, E18					Half-life increase
		Homsap IGHG1v22 CH2 Y15.1, T16, E18; CH3 K113, F114, H116	v22	CH2	Y15.1, T16, E18	CH3	K113, F114, H116			Half-life increase
		Homsap IGHG1v23 CH2 E1.2	v23	CH2	E1.2			ADCC reduction	CDC reduction
		Homsap IGHG1v24 CH3 L107, S114	v24			CH3	L107, S114			Half-life increase
		Homsap IGHG1v25 CH2 E29, F113	v25	CH2	E29, F113			B cell inhibition
		Homsap IGHG1v26 CH3 Y22	v26			CH3	Y22			Knob in knobs-into-holes interaction
		Homsap IGHG1v27 CH2 C3	v27	CH2	C3					Site-specific drug attachment engineered cysteine
		Homsap IGHG1v28 CH2 insC3A	v28	CH2	insC3A					Site-specific drug attachment engineered cysteine
		Homsap IGHG1v29 CH2 A84.4	v29	CH2	A84.4					No N-glycosylation site
		Homsap IGHG1v30 CH2 G84.4	v30	CH2	G84.4					No N-glycosylation site
		Homsap IGHG1v31 CH3 T86	v31			CH3	T86			Hole in knobs-into-holes interaction
		Homsap IGHG1v32 CH3 W22	v32			CH3	W22			Knob in knobs-into-holes interaction
		Homsap IGHG1v33 CH3 S22, A24, V86	v33			CH3	S22, A24, V86			Hole in knobs-into-holes interaction
		Homsap IGHG1v34 CH3	v34			CH3	G109			Favors hexamerisation
		Homsap IGHG1v35 CH2 E29	v35	CH2	E29				CDC enhancement
		Homsap IGHG1v36 CH2 Q84.4	v36	CH2	Q84.4					No N-glycosylation site
		Homsap IGHG1v37 h S5	v37	h	S5					No disulfide bridge inter H-L
		Homsap IGHG1v38 CH2 S108, F113	v38	CH2	S108, F113			Abrogation of FcyRIII binding	Abrogation of C1q binding
		Homsap IGHG1v39 CH2 F1.3, E1.2, S116	v39	CH2	F1.3, E1.2, S116			ADCC reduction	CDC reduction
		Homsap IGHG1v40 CH2 A1.3, A1.2, S116	v40	CH2	A1.3, A1.2, S116			ADCC reduction	CDC reduction
		Homsap IGHG1v41 CH2 F1.3, E1.2	v41	CH2	F1.3, E1.2			ADCC reduction	CDC reduction
		Homsap IGHG1v42 CH2 Q14, CH3 L107	v42	CH2	Q14	CH3	L107			Half-life increase
		Homsap IGHG1v43 CH2 A1.3, E1.2, A1	v43	CH2	A1.3, E1.2, A1			ADCC reduction	CDC reduction
		Homsap IGHG1v43-60 CH2 A1.3, E1.2, A1, S115, S116	v43-60	CH2	A1.3, E1.2, A1, S115, S116			ADCC reduction	CDC reduction
		Homsap IGHG1v44 CH2 C122	v44	CH2	C122					Site-specific drug attachment engineered cysteine
		Homsap IGHG1v45 CH2 A1.1, L115, E117	v45	CH2	A1.1, L115, E117			ADCC and ADCP enhancement
		Homsap IGHG1v46 CH3 K113, F114	v46			CH3	K113, F114			Half-life increase
		Homsap IGHG1v47 CH2 delG1.1	v47	CH2	delG1.1			ADCC reduction
		Homsap IGHG1v48 CH2 R113	v48	CH2	R113			ADCC reduction	CDC reduction
		Homsap IGHG1v49 CH2 G114	v49	CH2	G114			ADCC reduction	CDC reduction
		Homsap IGHG1v50 CH2 P1.4, V1.3, A1.2, delG1.1	v50	CH2	P1.4, V1.3, A1.2, delG1.1			ADCC reduction
		Homsap IGHG1v51 CH2 K29	v51	CH2	K29			ADCC reduction	CDC reduction
		Homsap IGHG1v52 CH2 R1.1, R113	v52	CH2	R1.1, R113			ADCC reduction
		Homsap IGHG1v53 CH2 F1.3, Q1.2, Q105	v53	CH2	F1.3, Q1.2, Q105			ADCC reduction	CDC reduction
		Homsap IGHG1v54 CH2 C83, C85	v54	CH2	C83, C85					Stabilizes CH2 in the absence of N84.4 glycosylation
		Homsap IGHG1v55 CH2 C123	v55	CH2	C123					Site-specific drug attachment engineered cysteine
		Homsap IGHG1v56 CH2 F85.2; CH3 F85.2	v56	CH2	F85.2	CH3	F85.2			Modified phenylalanine for conjugation
		Homsap IGHG1v59 CH2 S1.3, T1.2, R1.1	v59	CH2	S1.3, T1.2, R1.1			Abrogation of FcyRIII binding	Abrogation of C1q binding
		Homsap IGHG1v60 CH2 S115, S116	v60	CH2	S115, S116			ADCC reduction	CDC reduction
Homsap IGHG1v61 h S11	v61	h	S11					No disulfide bridge inter H-H
Homsap IGHG1v62 h S14	v61	h	S14					No disulfide bridge inter H-H
Homsap IGHG1v63 CH2 S2	v63	CH2	S2			ADCC reduction	CDC reduction
Homsap IGHG1v64 CH2 C36	v64	CH2	C36					Site-specific drug attachment engineered cysteine
Homsap IGHG1v65 CH2 delE1.4, delL1.3, delL1.2	v65	CH2	delE1.4, delL1.3, delL1.2			ADCC reduction	CDC reduction
Homsap IGHG1v66 CH2 A27	v66	CH2	A27			ADCC reduction
Homsap IGHG1v67 CH2 S27	v67	CH2	S27			ADCC reduction
Homsap IGHG1v68 CH3 V6, L22, L79, W81	v68			CH3	V6, L22, L79, W81			Enhances the heteropairing H-H of bispecific antibodies
Homsap IGHG1v69 CH3 V6, Y7,A85.1, V86	v69			CH3	V6, Y7,A85.1, V86			Enhances the heteropairing H-H of bispecific antibodies
Homsap IGHG1v70 h S5, S11, S14; CH2 S2	v70	h CH2	S5, S11, S14 S2			ADCC reduction	CDC reduction
Homsap IGHG1v71 CH2 A27, G116	v71	CH2	A27, G116			ADCC reduction	CDC reduction
Homsap IGHG1v72 CH2 E37	v72	CH2	E37			ADCC reduction Increases FcγRIIb binding
IGHG2
	Homsap IGHG2v1 CH2 L1.3, L1.2, G1.1, G1	v1	CH2	L1.3, L1.2, G1.1, G1			ADCC enhancement
	Homsap IGHG2v2 CH2 Q30, L92, S115, S116	v2	CH2	Q30, L92, S115, S116			ADCC reduction	CDC reduction
	Homsap IGHG2v3 CH2 A1.2, A1, S2, A30, L92, S115, S116	v3	CH2	A1.2, A1, S2, A30, L92, S115, S116			ADCC reduction	CDC reduction
	Homsap IGHG2v4 CH2 Q14	v4	CH2	Q14					Half-life increase
	Homsap IGHG2v5 CH3 L107	v5			CH3	L107			Half-life increase
	Homsap IGHG2v6 CH2 Q14, CH3 L107	v6	CH2	Q14	CH3	L107			Half-life increase
	Homsap IGHG2v7 CH2 Y85.2, L92, A339	v7	CH2	Y85.2, L92, A339			ADCC reduction	CDC reduction	Reduction of acid-induced aggregation
	Homsap IGHG2v8-1 CH2 A93	v8-1	CH2	A93					Half-life decrease
IGHG3	Homsap IGHG3v1 CH3 H115	v1			CH3	H115			Half-life increase
IGHG4
	Homsap IGHG4v1 CH2 L1.3	v1	CH2	L1.3			ADCC enhancement
	Homsap IGHG4v2 CH2 P116	v2	CH2	P116				CDC enhancement
	Homsap IGHG4v3 CH2 E1.2	v3	CH2	E1.2			ADCC reduction	CDC reduction
	Homsap IGHG4v3-49 CH2 E1.2, G114	v3-49	CH2	E1.2, G114			ADCC reduction	CDC reduction
	Homsap IGHG4v4 CH2 A1.3, A1.2	v4	CH2	A1.3, A1.2			ADCC reduction	CDC reduction
	Homsap IGHG4v5 h P10	v5	h	P10					Half-IG exchange reduction
	Homsap IGHG4v6 CH3 K88	v6			CH3	K88			Half-IG exchange reduction
	Homsap IGHG4v7 CH2 del 1.4, P1.3, V1.2, A1.1	v7	CH2	del 1.4, P1.3, V1.2, A1.1			ADCC reduction
	Homsap IGHG4v8 CH3 R115, F116, P125	v8			CH3	R115, F116, P125			Abrogation of binding to Protein A
	Homsap IGHG4v10 CH3 L85.1, K88	v10			CH3	L85.1, K88			Half-IG exchange reduction of bispecific IgG4
	Homsap IGHG4v21 CH2 Y15.1, T16, E18	v21	CH2	Y15.1, T16, E18					Half-life increase
	Homsap IGHG4v22 CH2 T16, P91, CH3 A114	v22	CH2	T16, P91	CH3	A114			Half-life increase
	Homsap IGHG4v24 CH3 L107, S114	v24			CH3	L107, S114			Half-life increase
	Homsap IGHG4v36 CH2 Q84.4	v36	CH2	Q84.4					No N-glycosylation site
	Homsap IGHG4v37 CH2 P1.4, V1.3, A1.2, A27, V92	v37	CH2	P1.4, V1.3, A1.2, A27, V92			ADCC reduction	CDC reduction
	Homsap IGHG4v38 CH2 P1.4, V1.3, A1.2, G1.1del	v38	CH2	P1.4, V1.3, A1.2, G1.1del			ADCC reduction	CDC reduction
	Homsap IGHG4v49 CH2 G114	v49	CH2	G114			ADCC reduction	CDC reduction
IGHG1-IGHG3
IGHG1-IGHG3	Homsap IGHG1G3v1 CH2 Q38, K40, F85.2	v1	CH2	Q38, K40, F85.2				CDC enhancement
IGHG2-IGHG4
IGHG2-IGHG4	Homsap IGHG2G4v1 CH2 delE1.4, P1.3, V1.2, A1.1	v1	CH2	delE1.4, P1.3, V1.2, A1.1			ADCC reduction	CDC reduction
Mus musculus	IGHG2B
		Musmus IGHG2Bv1 CH2 L1.2	v1	CH2	L1.2			ADCC enhancement
		Musmus IGHG2Bv2 CH2 A101	v2	CH2	A101				CDC reduction
		Musmus IGHG2Bv3 CH2 A103	v3	CH2	A103				CDC reduction
		Musmus IGHG2Bv4 CH2 A105	v4	CH2	A105				CDC reduction
Canis lupus familiaris	IGHG2
		Canlupfam IGHG2v1 CH2 A1.3, A1.2, A1	v1	CH2	A1.3, A1.2, A1			ADCC reduction	CDC reduction
		Canlupfam IGHG2v2 CH2 A1.3, A1.2, G114	v2	CH2	A1.3, A1.2, G114			ADCC reduction	CDC reduction
		Canlupfam IGHG2v29 CH2 A84.4	v29	CH2	A84.4					No N-glycosylation site

More information:

ADCC and CDC (IMGT Lexique)
Correspondence between C numberings (IMGT Scientific chart)
Half-IG exchange (The IMGT Biotechnology page)
IGHG CH properties and antibody engineering (IMGT Lexique)
IMGT description of mutations
Knobs-into-holes amino acid changes (The IMGT Biotechnology page)
Protein display : house mouse (Mus musculus) IGHC (IMGT Repertoire)
Protein display : human (Homo sapiens) IGHC (IMGT Repertoire)
The Immunoglobulin FactsBook (FactsBook) (IMGT Index)

The IMGT Biotechnology page

http://www.imgt.org

IMGT engineered variant nomenclature: IGHG variants